Capabilities by Industry: Healthcare
Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector. Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe and Australia have executed many of the most significant and complex transactions for some of the leading companies in the industry.
In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.
Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals; and biotechnology.
Below we highlight a few of the transactions on which we have advised in this area:
Recent Transactions
Sort By
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
Centogene GmbH
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
Medical Review Institute of America
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
myHomecare Group
Advising Australian Unity on its acquisition of myHomecare Group